Axil Capital was spun out of Mizuho Securities in 2017, with early investors that include Mizuho, the Japanese government, a global pharma, and a small group of visionary investors from inside and outside of Japan. Our goal is to create synergies between the biotech ecosystem in Japan and the rest of the world, resulting in great companies and great returns for our investors.
We specialize in biomedical & healthcare technology investments, with emphasis on supporting the growth of early stage ventures. Our interests are broad. They span the entire spectrum of life sciences, including regenerative medicine and standard therapeutics to cross-disciplinary technologies that can transform the future of healthcare (AI, robotics, distributed computing, etc.). Our actions are focused on projects where we can unlock the hidden value with our global network, which brings together unique expertise from industry and academia, across the value chain.
Axil Capital Partners LLP (General Partner): Management and operation of venture capital funds.
Axil Capital Advisors K.K.: Basic research and analysis of technologies and ventures.
Axil Life Science & Healthcare Fund No.1 L.P. (ALHF I)
Head Office Location
Nihonbashi Life Science Building 2 504
3-11-5 Nihonbashi-Honcho, Chuo-ku, Tokyo 103-0023